^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Yervoy (ipilimumab)

    i
    Other names: BMS-734016, MDX 101, MDX 010, MDX-CTLA-4, MDX-CTLA5, BMS734016
    Company:
    BMS, Ono Pharma
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    1d
    Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases (clinicaltrials.gov)
    P1, N=10, Recruiting, Emory University | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial primary completion date • Checkpoint inhibition • Surgery
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)
    1d
    DynaMO: Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=196, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2025 --> Mar 2026 | Trial primary completion date: May 2025 --> Mar 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    AR (Androgen receptor)
    |
    Yervoy (ipilimumab) • carboplatin • abiraterone acetate • cabazitaxel • Erleada (apalutamide)
    1d
    Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary (clinicaltrials.gov)
    P1, N=1, Terminated, Abramson Cancer Center at Penn Medicine | Active, not recruiting --> Terminated; failure to accrue
    Trial termination • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • capecitabine
    2d
    Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights. (PubMed, Open Respir Arch)
    Innovative combination regimens, exemplified by the concurrent administration of nivolumab and ipilimumab, have demonstrated marked improvement in survival and patient's benefits. This review accentuates the transformative capacity of immunotherapy in revolutionizing the therapeutic outlook for MPM, thereby potentially translating into augmented survival rates and offering glimpses of new approaches on the horizon. Despite the persisting challenges, the synergistic crossroads of interdisciplinary research and collaborative clinical endeavors portend a hopeful landscape for MPM treatment.
    Review • Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • PD-1 (Programmed cell death 1) • BAP1 (BRCA1 Associated Protein 1) • NF2 (Neurofibromin 2) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    BAP1 mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    2d
    NCI-2016-00661: Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=80, Active, not recruiting, M.D. Anderson Cancer Center | N=45 --> 80
    Enrollment change
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    2d
    EMPOWER-Lung 3: Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer (clinicaltrials.gov)
    P3, N=790, Active, not recruiting, Regeneron Pharmaceuticals | Trial primary completion date: Jul 2023 --> Feb 2025
    Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Yervoy (ipilimumab) • Libtayo (cemiplimab-rwlc)
    3d
    A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms (clinicaltrials.gov)
    P1, N=60, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jul 2028 --> Nov 2027
    Trial completion date
    |
    Yervoy (ipilimumab)
    4d
    Predictive factors of nivolumab plus ipilimumab treatment efficacy in metastatic renal cell carcinoma patients. (PubMed, Jpn J Clin Oncol)
    Patients without cytoreductive nephrectomy and with bone metastasis, liver metastasis, high C-reactive protein levels and paraneoplastic symptoms were significantly correlated with shorter progression-free survival. The presence of paraneoplastic symptoms was an independent predictor of progression-free survival. Improvement in paraneoplastic symptoms may reflect the treatment efficacy of nivolumab plus ipilimumab.
    Journal • Metastases
    |
    CRP (C-reactive protein)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    4d
    Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Vyriad, Inc. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • IFNB1 (Interferon Beta 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Voyager-V1
    4d
    CHINOREC: Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer (clinicaltrials.gov)
    P2, N=80, Completed, Johannes Laengle, MD, PhD | Recruiting --> Completed | Trial completion date: Dec 2024 --> Mar 2024 | Trial primary completion date: Jun 2024 --> Mar 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • capecitabine
    5d
    A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, University Health Network, Toronto
    New P1 trial • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    8d
    CARE1 Pragmatic Clinical Trial (clinicaltrials.gov)
    P3, N=1250, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Lenvima (lenvatinib) • Cabometyx (cabozantinib tablet) • Inlyta (axitinib)
    8d
    DREAMseq: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (clinicaltrials.gov)
    P3, N=300, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    BRAF mutation • BRAF V600
    |
    THXID® BRAF Kit • cobas® 4800 BRAF V600 Mutation Test
    |
    Opdivo (nivolumab) • Mekinist (trametinib) • Yervoy (ipilimumab) • Tafinlar (dabrafenib) • ABP 206 (nivolumab biosimilar)
    9d
    SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=45, Recruiting, Sarcoma Oncology Research Center, LLC | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Yondelis (trabectedin)
    9d
    INITIUM: UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma (clinicaltrials.gov)
    P2, N=156, Completed, Ultimovacs ASA | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Apr 2024 | Trial primary completion date: Apr 2024 --> Jan 2024
    Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Leukine (sargramostim) • UV1
    10d
    Autopsy case of meningoencephalitis induced by nivolumab and ipilimumab in a patient being treated for non-small cell lung cancer. (PubMed, Intern Med)
    A 75-year-old woman with stage IVB (cT2bN3M1b) lung adenocarcinoma was administered nivolumab, ipilimumab, carboplatin, and paclitaxel. An autopsy showed encephalitis and CD8+ lymphocyte infiltration around the blood vessels. Thus, immune-related adverse events should be suspected and treatment should be initiated for patients presenting with an impaired consciousness when concurrently being treated with nivolumab and ipilimumab.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel
    10d
    C-IT Neo: CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma (clinicaltrials.gov)
    P2, N=28, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Surgery • Pre-surgery
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    10d
    Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=20, Recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • everolimus • Lenvima (lenvatinib) • Cabometyx (cabozantinib tablet)
    11d
    INSPIRE: Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=69, Active, not recruiting, Radboud University Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Feb 2026 | Trial primary completion date: Jan 2025 --> Aug 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • CDK12 (Cyclin dependent kinase 12)
    |
    TMB-H
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    12d
    Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study. (PubMed, BMC Cancer)
    The RP2D binimetinib regimen had a safety profile similar to previous binimetinib studies or nivolumab and ipilimumab combination studies. There was a lack of clinical benefit with either drug combination. Therefore, these data do not support further development of binimetinib in combination with nivolumab or nivolumab and ipilimumab in RAS-mutated MSS mCRC.
    P1/2 data • Clinical Trial,Phase II • Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    MAP2K2 (Mitogen-activated protein kinase kinase 2) • RAS (Rat Sarcoma Virus)
    |
    RAS mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Mektovi (binimetinib)
    12d
    DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, University of Alabama at Birmingham
    New P2 trial • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed
    12d
    NeoRelapse: Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, University of Utah
    New P2 trial
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    12d
    CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma (clinicaltrials.gov)
    P2, N=16, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Apr 2024 | Trial primary completion date: Jan 2025 --> Apr 2024
    Trial completion • Trial completion date • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene) • IL2 (Interleukin 2) • MLANA (Melan-A)
    |
    BRAF mutation • BRAF V600
    |
    Yervoy (ipilimumab) • cyclophosphamide • Proleukin (aldesleukin)
    12d
    CARE1 Pragmatic Clinical Trial (clinicaltrials.gov)
    P3, N=1250, Not yet recruiting, Gustave Roussy, Cancer Campus, Grand Paris
    New P3 trial • Metastases
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Lenvima (lenvatinib) • Cabometyx (cabozantinib tablet) • Inlyta (axitinib)
    14d
    Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas. (PubMed, Pharmacol Res)
    When the tumors have metastasized, systemic therapy with protein-tyrosine kinase antagonists including sorafenib, sunitinib, pazopanib, and tivozanib that target vascular endothelial, platelet-derived, fibroblast, hepatocyte, and stem cell factor growth factor receptors (VEGFR, PDGFR, FGFR, MET, and Kit) were prescribed after 2005. The monoclonal antibody immune checkpoint inhibitor nivolumab (targeting PD1) was approved for the treatment of RCCs in 2015. It is usually used now in combination with ipilimumab (targeting CTLA-4) or cabozantinib (a multikinase blocker). Other combination therapies include pembrolizumab (targeting programed cell death protein 1) and axitinib (a VEGFR and PDGFR blocker) or lenvatinib (a multikinase inhibitor). Since the KEYNOTE-426 clinical trial, the use of immune checkpoint inhibitors in combination with protein-tyrosine kinase inhibitors is now the standard of care for most patients with metastatic renal cell carcinomas and monotherapies are used only in those individuals who cannot receive or tolerate immune checkpoint inhibitors.
    Review • Journal
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Yervoy (ipilimumab) • sorafenib • Sutent (sunitinib) • everolimus • Lenvima (lenvatinib) • Bavencio (avelumab) • Votrient (pazopanib) • Cabometyx (cabozantinib tablet) • Torisel (temsirolimus) • Inlyta (axitinib) • Welireg (belzutifan) • Fotivda (tivozanib)
    15d
    A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients with Unresectable Stage III and IV Melanoma (ACTRN12617000772347)
    P1/2, N=72, Completed, Peter MacCallum Cancer Centre | Active, not recruiting --> Completed
    Trial completion
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Prolia (denosumab)
    15d
    NCI-2018-03329: Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer (clinicaltrials.gov)
    P1, N=7, Completed, Claire Verschraegen | Active, not recruiting --> Completed
    Trial completion
    |
    CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    15d
    A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy (clinicaltrials.gov)
    P1/2, N=126, Not yet recruiting, 7 Hills Pharma, LLC
    New P1/2 trial • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • alintegimod (7HP349)
    16d
    Real-world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non-small cell lung cancer. (PubMed, Thorac Cancer)
    In real-world practice, CP demonstrated superior PFS compared with CNI. These findings can inform treatment selection in advanced NSCLC.
    Journal • HEOR • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)
    17d
    When Hormones are Being Difficult: A Rare Case and the Literature Review of Pembrolizumab-Induced Polyendocrinopathy. (PubMed, J Community Hosp Intern Med Perspect)
    Immune Checkpoint inhibitors (ICIs) such as nivolumab, pembrolizumab, and ipilimumab are monoclonal antibodies against cytotoxic T lymphocyte antigen 4 (CTLA4) or program death (PD)1 and its ligand PDL1...After discharge from the hospital on insulin and levothyroxine therapy, the patient reported increasing fatigue and further testing revealed low cortisol levels <0.5 mcg/dl with elevated ACTH consistent with primary adrenal insufficiency. The patient was started on hydrocortisone therapy with improvement in symptoms...Only a few cases of pembrolizumab-induced polyendocrinopathy have been reported so far which we have mentioned in this article. While patients are on immunotherapy, close monitoring for clinical signs & symptoms can lead to an early diagnosis, substantially improving morbidity and mortality.
    Review • Journal
    |
    PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)
    17d
    Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party. (PubMed, Mol Ther Oncol)
    Currently, seven ICIs, namely ipilimumab (anti-cytotoxic T lymphocyte-associated protein 4 [CTLA4]), pembrolizumab, nivolumab (anti-programmed cell death protein 1 [PD-1]), atezolizumab, avelumab, durvalumab, and cemiplimab (anti-PD-L1), have been approved for various cancer types. Consequently, ongoing studies are evaluating the next generation of ICIs, such as lymphocyte activation gene-3 (LAG3), T cell immunoglobulin and mucin-domain containing 3 (TIM3), and T cell immunoglobulin and ITIM domain (TIGIT). Our review provides a summary of clinical trials evaluating these novel immune checkpoints in cancer treatment.
    Review • Journal
    |
    LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • Libtayo (cemiplimab-rwlc)
    17d
    CheckMate901: Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer (clinicaltrials.gov)
    P3, N=1290, Active, not recruiting, Bristol-Myers Squibb | Trial primary completion date: Apr 2024 --> Oct 2024
    Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • gemcitabine
    17d
    Pan Tumor Rollover Study (clinicaltrials.gov)
    P2, N=1500, Recruiting, Bristol-Myers Squibb | N=800 --> 1500 | Trial completion date: Aug 2025 --> Aug 2029 | Trial primary completion date: Aug 2025 --> Aug 2029
    Enrollment change • Trial completion date • Trial primary completion date • Pan tumor
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Yervoy (ipilimumab) • 5-fluorouracil • Sutent (sunitinib) • temozolomide • capecitabine • Xtandi (enzalutamide capsule) • Cabometyx (cabozantinib tablet) • Rubraca (rucaparib) • Stivarga (regorafenib) • pemetrexed • oxaliplatin • Darzalex (daratumumab) • leucovorin calcium • Opdualag (nivolumab/relatlimab)
    18d
    Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Apr 2025 | Trial primary completion date: Dec 2024 --> Apr 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • CRS-207
    18d
    XH001 Combination With Ipilimumab and Chemotherapy for Patients With Resected Pancreatic Cancer (clinicaltrials.gov)
    P=N/A, N=12, Not yet recruiting, Wu Wenming
    New trial
    |
    Yervoy (ipilimumab) • capecitabine • XH001
    19d
    IOV-COM-202: Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors (clinicaltrials.gov)
    P2, N=178, Recruiting, Iovance Biotherapeutics, Inc. | Trial completion date: Dec 2024 --> Aug 2029 | Trial primary completion date: Dec 2023 --> Aug 2029
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Amtagvi (lifileucel) • LN-145 • LN-145-S1
    19d
    CYTOSHRINK: SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, Ontario Clinical Oncology Group (OCOG) | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    22d
    BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab (clinicaltrials.gov)
    P2, N=25, Recruiting, Brown University | Trial primary completion date: Dec 2023 --> Apr 2024
    Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    22d
    Development and Analysis of a Stool Bank for Cancer Patients (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Persephone Biosciences | Active, not recruiting --> Recruiting | Trial completion date: Dec 2022 --> Dec 2028 | Trial primary completion date: Dec 2022 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Actemra IV (tocilizumab)
    23d
    A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab (clinicaltrials.gov)
    P2, N=14, Terminated, Georgetown University | Unknown status --> Terminated; Lack of Enrollment
    Trial termination • Combination therapy • Tumor mutational burden • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    23d
    A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden (clinicaltrials.gov)
    P2; Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
    Checkpoint inhibition • Trial completion date • Trial primary completion date • Tumor mutational burden • IO biomarker • Checkpoint block
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler)
    |
    TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • TERT mutation • IDH wild-type • TERT promoter mutation
    |
    FoundationOne® CDx
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    23d
    CYTOSHRINK: SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (clinicaltrials.gov)
    P2, N=78, Recruiting, Ontario Clinical Oncology Group (OCOG) | Trial completion date: Mar 2024 --> Mar 2025
    Trial completion date • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)